Biocon Biologics sees insulin demand growing across markets, says CEO Tambe
Subscribe to enjoy similar stories. Biocon Biologics Ltd expects a significant rise in demand for its insulin products across geographies in the coming months and years, managing director and chief executive Shreehas Tambe said on Friday. “What we are certainly seeing is an increasing demand for our insulin products…not just in the US and Europe but also in emerging markets," Tambe told Mint in an interview.
“We consider diabetes and insulin particularly as a big differentiator [for us] because the world is going to need insulin and it's not going away," Tambe added. Also Read | Biocon Biologics to sell India branded formulations biz to Eris for ₹1,242 cr Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and Ustekinumab in autoimmune therapy. The company is also awaiting approval for its biosimilar Denosumab, used to treat osteoroposis, after which the product will be launched.
Biocon also has three products lined up for launch in Europe. Also Read | Biocon Biologics integrates Vitaris’ biosimilars business “The biggest tailwind that we’ve is that the therapy areas that we operate in happen to be the therapy areas that global healthcare spends are aligned on…diabetes, oncology and autoimmune diseases. And if you look at the portfolio that we have, it completely aligns with them," Tambe said.
Read more on livemint.com
